Synaptogenix’s Bryostatin-1 in Alzheimer’s shows positive Phase 2 results

Synaptogenix announced that an abstract featuring secondary endpoint data of its National Institutes of Health sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization World Congress of Neuroscience to be held in September 2023 in Spain. In the recently completed Phase 2 clinical trial of Bryostatin-1, two cohorts were studied: a Moderate Cohort and a Severe Cohort. While Moderate Cohort patients showed no significant benefit, for patients of the Severe Cohort, representing the patient population with the most advanced Alzheimer’s disease – AD -, nearly all pre-specified secondary endpoints were achieved with statistical significance. Data also showed statistical significance in exploratory secondary endpoints for this Severe Cohort, and post hoc analysis was positive.